Anavex Life Sciences Corp (AVXL)

[seventhwave]

CTAD will hopefully give us a bash proof bunch of PR's.

AVXL will have data that is certainly encouraging to our eyes and rightfully so within bounds.

But the market (esp Adam F & the french shorter @JFinDallas) will be all over it with "meaningless n=32, now 25" and "characterization", heavy data mining with Ariana, yada yada... The "adaptive" nature of the trial will be put in negative light and the key takeaway of SUSTAINED BENEFIT and even IMPROVEMENT over a LONG period, never before demonstrated in Alz treatment will be ignored. That's how the market deals with biotech microcaps - anything short of unequivocal is pounded and hope is always a casualty.

The redeeming factor likely to counter the FUD and put wind in the sails of $AVXL stock is accompanying PR for the start of 3 trials.